GATA ROIDAL RECORD Q FILING NEWZZZ !! Reports Record First

New Post Public Reply Private Reply Replies (0) Message Board

Nov 15, 2012 at 9:25 AM

[b]GATA > ROIDAL RECORD Q FILING NEWZZZ !! Reports Record First Quarter Revenues, Adoption Of IFRS Accounting Standard In Anticipation Of Applying For Listing On The NASDAQ Bulletin Board
[/b]
2012-11-14 07:00 ET - News Release

MUMBAI, India, Nov. 14, 2012 /PRNewswire/ -- Groupe Athena, Inc. (Pink sheets: GATA) announced today record revenues of $15,367,544 for the first quarter ending September 30, 2012, which is a 25% increase over the same period in 2011. Net after tax income for the period was $1,307,293 or $.03 per share which included a one time expense of $407,181 related to the purchase of the company's new facility in India. Trailing twelve month (ttm) earnings remained strong at nearly $.10 per share. The company also has a very healthy cash position and no long term debt.

The Company's Chairman, D. Purohit stated, "The pharma industry within our region is still very robust and Groupe Athena is extremely well positioned to continue on our current growth track for the foreseeable future. And with the recently reported asset additions which allow us to perform more services in-house, our margins are also increasing significantly."

In other news the Company has completed their recent transition from GAAP to the International Financial Reporting Standard (IFRS) for all future audited financials. The Company's annual report for the recent fiscal yearend on June 30, 2012 which was released on August 20, 2012 was audited using IFRS. With the completion of the audit for this fiscal year end on June 30, 2013 the company will seek to qualify for listing on the NASDAQ Bulletin Board quotation system.

To review the complete quarterly report please go to www.otcmarkets.com/stock/GATA/quote and click on "Financials."

The company reports it is still committed to funding all capital expenditures entirely from internal cash accruals without any shareholder dilution or debt increases.

As was previously stated, the Indian pharmaceutical industry is increasingly focusing on exports to the United States and GATA is well positioned to help them get their products approved by the FDA for sales in the US. All of these are potential clients and the Company believes it has an advantage over competitors due to the facilities based in India, and their ability to deliver quick feedback to clients that could result in expedited order generation. With recent additions to equipment, the company will continue to take on additional contracts and continue to anticipate further growth.

About Groupe Athena, Inc.

Groupe Athena Inc. was incorporated in June 2008 and began operations on July 1 of that year. The company is a research and testing organization and helps various pharmaceutical and medical products and devices companies in India and Southeast Asia to get regulatory approvals and facilitate exports of their products to the United States. The Company accomplishes this by assisting clients from concept through development, providing consultation on regulatory requirements, filings and processes.

The company has a research and marketing facility in India that currently employs 17 consultants and marketing personnel and is working towards aggressively expanding its presence in the Indian pharmaceutical industry. The Company's web address is www.groupeathena.com

For more information contact:
Paul Cornell
Corporate Shareholder Relations, Inc.
pcornell@totalpublicrelations.com

Safe Harbor Statement
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate", "project", "intend", "forecast", "anticipate", "plan", "planning", "expect", "believe", "will likely", "should", "could", "would", "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- activities of competitors and the presence of new or additional competition and conditions of equity markets.

SOURCE Groupe Athena, Inc.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

APP Group's New Conservation Efforts in Sumatra

Taking a Bold Step Towards Conservation APP Group, in collaboration with Proforest, WWF-Indonesia, and KKI WARSI, is setting its sights on a more sustainable future with the PROTECT30 initiative. This isn't just another dime-a-dozen CSR project—it’s a concerted effort aimed at conserving Sumatra's precious Bukit Tigapuluh landscape. These folks are playing the long...

Sussex County Data Breach Raises Security Concerns

The Digital Fiasco: A Wake-Up Call Straight out of Sussex County in good ol' New Jersey, we’re staring down another data breach, folks. When you hear about a data privacy incident, there's always that same sinking feeling of another layer of personal security peeled away. This time, the Sussex County Prosecutor's Office got caught in the crossfire, with personal info...

Future FinTech Under Investigation: Shareholder Impact Looms

Future FinTech Faces Legal Scrutiny When the walls close in under financial suspicion, the spotlight can burn brighter than any anticipated market gain. That's precisely what Future FinTech Group Inc. (NasdaqCM: FTFT) is up against now. Kahn Swick & Foti, LLC, featuring the ex-Attorney General of Louisiana, Charles C. Foti, Jr., has begun scrutinizing the actions of...

New Frontiers in Glaucoma Care: Less Drops Required?

Eyeing New Glaucoma Treatment Strategies You think glaucoma treatment is all about popping eye drops day in and day out? Well, turns out, things are shifting down in Racine, Wisconsin. Folks at HelloNation have been spilling the beans on earlier glaucoma interventions that might just lighten your load of daily medications. Doctors I. Paul Singh and R. Krishna Sanka...

Johnson & Johnson Unveils Promising PsA Treatment Data

A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...

J&J's New Study: Sjögren’s Solution Insight Sparks Debate

Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...

212NYC Gala Celebrates Ad Industry's Human Touch

The Advertising Gala with Heart When you toss nearly 300 advertising honchos into a room at Tribeca's Rooftop, you don't just get another bash; you get an industry checkpoint. This time, the 212NYC shindig on November 5, 2026, wasn't just about stroking egos. It was about spotlighting the soul in business, right when AI threatens to run wild with it. Navigating AI's...

Madrigal Faces Legal Scrutiny Amid Whistleblower Claims

The Storm Brewing Over Madrigal Pharmaceuticals Well, folks, here we are smack dab in the middle of another roller-coaster ride in the biotech sector, and it ain't pretty. Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is in hot water with some serious allegations thrown their way. The company is now under investigation by Kessler Topaz Meltzer & Check, LLP, a top-notch...

Paris Baguette Pioneers Drive-Thru in Oklahoma

Tapping The Unseen Potential In Bakery Cafes Every so often a business move comes along that makes you sit up and say, "Why the hell haven't they done this before?" Paris Baguette has finally cracked that code, rolling out its first-ever drive-thru in Moore, Oklahoma. Now, imagine yourself zipping through for a croissant without leaving the comfort of your car seat. Makes...

Aurora Innovation Faces Legal Heat Amid Delays

Production Snags at Aurora Innovation Ah, investing – not for the faint-hearted. One day you're riding high, the next you're scraping by, and Aurora Innovation's (NASDAQ:AUR) investors just hit a rough patch. The autonomous trucking darling announced unexpected delays in its delivery schedule, sending shockwaves through its stock price and shaking investor confidence....